3T Biosciences

Stanford spinout 3T Bio snags $40M for immunotherapies targeted to solid tumors

Artificial intelligence and machine learning are key to 3T Biosciences’ approach to identifying novel drug targets and engineering better, safer cancer immunotherapies. The Stanford spinout is now out of stealth with a $40 million Series A financing and a plan to reach the clinic within two years.

By Frank Vinluan

Startups, BioPharma

Report: Sean Parker and Peter Thiel back cancer immunotherapy startup 3T Biosciences

Thiel and Parker were part of a more than $12 million funding round for the stealth immunotherapy business,

By Stephanie Baum

With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?

Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.